Related Experiment Video
Updated: Aug 18, 2025
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis
Donald C Moore1, Justin R Arnall2
1Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Insights
Sutimlimab offers a new treatment for cold agglutinin disease (CAD)-associated hemolysis, rapidly improving hemoglobin levels and quality of life. While effective, patients may experience infusion reactions and increased risk of serious infections.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia.
- Hemolysis in CAD is mediated by the complement system.
- Current treatment options for CAD are limited.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and therapeutic role of sutimlimab.
- To evaluate sutimlimab as a treatment for CAD-associated hemolysis.
Main Methods:
- Literature search of PubMed, prescribing information, meeting abstracts, and clinicaltrials.gov.
- Review of published prospective clinical trials and abstracts on sutimlimab for CAD treatment.
- Data synthesis from phase III CARDINAL and CADENZA trials.
Main Results:
- Sutimlimab, a complement C1s inhibitor, is indicated for CAD-associated hemolysis.
- The CARDINAL trial showed 54% of patients achieved target hemoglobin levels.
- The CADENZA trial demonstrated significant improvements in hemoglobin and reduced need for transfusions/additional therapies compared to placebo.
Conclusions:
- Sutimlimab effectively halts hemolysis and improves hemoglobin and quality of life in CAD patients.
- It represents a novel therapeutic option for CAD-associated hemolysis.
- Potential safety concerns include infusion reactions and risk of serious infections.
Objective:
To review the pharmacology, pharmacokinetics, efficacy, safety, dosing and administration, and place in therapy of sutimlimab for the management of cold agglutinin disease (CAD)-associated hemolysis.
Data Sources:
A literature search of PubMed (1966-October 2022) was conducted using the keywords sutimlimab, BIVV009, and cold agglutinin. Data were also obtained from prescribing information, meeting abstracts, and clinicaltrials.gov.
Study Selection And Data Extraction:
All published prospective clinical trials, prescribing information, and meeting abstracts on sutimlimab for the treatment of CAD were reviewed.
Data Synthesis:
Sutimlimab is a first-in-class complement C1s inhibitor indicated for the treatment of CAD-associated hemolysis. This approval was based on the phase III CARDINAL trial, which evaluated sutimlimab in patients with CAD-associated hemolysis. The primary endpoint of achieving a hemoglobin of ≥12 g/dL or increase of ≥2 above baseline was achieved by 54% of patients with sutimlimab in the 26-week trial. The phase III CADENZA trial was a placebo-controlled trial in which sutimlimab has demonstrated a significant improvement in the composite endpoint of hemoglobin increase of ≥1.5 g/dL, avoidance of transfusion, and avoidance of additional CAD therapies (73% sutimlimab vs 15% placebo).
Relevance To Patient Care And Clinical Practice In Comparison With Existing Drugs:
Sutimlimab rapidly halts hemolysis, improves hemoglobin, and improves quality-of-life in patients with CAD. Safety issues with sutimlimab include infusion-related reactions and risk of serious infections with encapsulated bacteria.
Conclusions:
Sutimlimab provides an additional therapeutic option in the treatment of CAD-associated hemolysis that can lead to rapid improvement in hemoglobin and anemia-related symptoms.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Related Concept Videos
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:27Complement System
01:26Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...